`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`MYLAN PHARMACEUTICALS INC.,
`Petitioner
`
`v.
`REGENERON PHARMACEUTICALS, INC.,
`Patent Owner
`
`
`Case IPR2021-00881
`Patent 9,254,338 B2
`
`
`PETITIONER’S IDENTIFICATION OF STATEMENTS SUPPORTED BY
`OBJECTED TO REFERENCES IN PATENT OWNER RESPONSES
`
`
`
`Case No. IPR2021-00881
`
`In accordance with the Board’s order during the teleconference held on
`
`February 23, 2022, Petitioner hereby submits this chart to identify statements in
`
`Patent Owner’s Responses supported by references that Petitioner objects to for non-
`
`compliance with 37 CFR § 42.6(a)(3) and/or 37 CFR § 42.24(b)(2). (Ex. 1100,
`
`Transcript of Teleconference Proceedings held on February 23, 2022, at 16:22-19:1).
`
`Statement Location
`
`IPR2021-00881
`Patent No. 9,254,338:
`• Paper 40, Patent
`Owner Response, filed
`February 11, 2022
`(“POR”).
`• Section VIII.B. (Paper
`40 at 58-62, entitled
`“Objective Evidence
`Confirms the Non-
`Obviousness of the
`Claimed Dosing
`Regimen”).
`
`IPR2021-00881
`Patent No. 9,254,338:
`• Paper 40, POR.
`• Section I. (Paper 40
`at 1-3, entitled
`“Introduction”).
`
`Objected to References
`(37 CFR § 42.6(a)(3))
`
`Word Count of Objected
`to References
`(37 CFR § 42.24(b)(2))
`
`Ex.2051, Do Declaration
`¶¶98-133, 135-170
`
`
`Ex.2051, ¶¶98-133 and
`135-170 account for 6071
`additional words.
`
`Ex.2052, Manning
`Declaration ¶¶29-42
`
`
`Ex.2052, ¶¶29-42
`account for 2436
`additional words;
`Ex.2052, ¶¶29-42 further
`cite 12 pages of
`appendices and 385
`pages of exhibits.
`
`
`
`1
`
`
`
`Statement Location
`
`Objected to References
`(37 CFR § 42.6(a)(3))
`
`Ex.2052, Manning
`Declaration ¶¶48-117
`
`
`Case No. IPR2021-00881
`
`Word Count of Objected
`to References
`(37 CFR § 42.24(b)(2))
`
`Ex.2052, ¶¶48-117
`account for 12,500
`additional words
`Ex.2052, ¶¶48-117
`further cite 138 pages of
`appendices and 27,861
`pages of exhibits.
`
`IPR2021-00881
`Patent No. 9,254,338:
`• Paper 40, POR
`• Section VIII.B. (Paper
`40 at 58-62, entitled
`“Objective Evidence
`Confirms the Non-
`Obviousness of the
`Claimed Dosing
`Regimen”).
`
`IPR2021-00881
`Patent No. 9,254,338:
`• Paper 40, POR, filed
`February 11, 2022.
`• Section VIII.B. (Paper
`40 at 58-62, entitled
`“Objective Evidence
`Confirms the Non-
`Obviousness of the
`Claimed Dosing
`Regimen”).
`
`Ex.2050, Brown
`Declaration ¶¶150-181
`
`
`
`Ex.2050, ¶¶150-181
`account for 2,757
`additional words.
`
`
`
`
`2
`
`
`
`Case No. IPR2021-00881
`
`Word Count of Objected
`to References
`(37 CFR § 42.24(b)(2))
`
`Patent Owner’s Claim
`Construction arguments
`for IPR2021-00881 are
`found on pages 7-24
`(Section IV) of its POR.
`(IPR2021-00881, Paper
`40 at 7-24).
`PO’s objected to
`reference accounts for
`4222 additional words.
`
`Statement Location
`
`Objected to References
`(37 CFR § 42.6(a)(3))
`
`IPR2021-00880
`Patent No. 9,669,069:
`• Paper 39, POR.
`• Section IV. (Paper 39
`at 7-9, entitled “Claim
`Construction”).
`
`CLAIM
`CONSTRUCTION
`Patent Owner states that
`it “does not advance
`claim construction
`positions” in this matter,
`IPR2021-00880.
`(IPR2021-00880, Paper
`39 at 8).
`In footnote, Patent
`Owner states that “if the
`Board decides to construe
`‘method of treating’ or
`‘tertiary dose’ in this
`IPR,” then the Board
`should do so consistent
`with Patent Owner’s
`arguments set forth in its
`POR for IPR2021-
`00881. (IPR2021-00880,
`Paper 39 at 8, fn. 5).
`
`
`
`3
`
`
`
`Dated: February 28, 2022
`
`
`
`
`
`
`
`
`
`
`Case No. IPR2021-00881
`
`Respectfully Submitted,
`
`RAKOCZY MOLINO MAZZOCHI SIWIK LLP
`
`/Paul J. Molino/
`Paul J. Molino
`Registration No. 45,350
`6 West Hubbard Street
`Chicago, IL 60654
`Telephone:
`(312) 222-6300
`Facsimile:
`(312) 843-6260
`paul@rmmslegal.com
`
`
`Counsel for Petitioner
`
`4
`
`
`
`
`
`
`
`
`
`Case No. IPR2021-00881
`
`CERTIFICATE OF SERVICE
`The undersigned hereby certifies that a true and correct copy of the foregoing
`
`Petitioner’s Identification Of Statements Supported By Objected To References In
`
`Patent Owner Responses was served on February 28, 2022, via electronic mail by
`
`agreement of the parties, to the following counsel for record of Patent Owners:
`
`Deborah E. Fishman (Reg. No. 48,621)
`David A. Caine (Reg. No. 52,683)
`Arnold & Porter Kaye Scholer LLP
`3000 El Camino Real
`Five Palo Alto Square, Suite 500
`Palo Alto, California 94306-3807
`Telephone: 650.319.4519
`Telephone: 650.319.4710
`Facsimile: 650.319.4573
`Deborah.Fishman@arnoldporter.com
`David.Caine@arnoldporter.com
`RegeneronEyleaIPRs@arnoldporter.com
`
`Daniel Reisner
`Matthew M. Wilk
`Arnold & Porter Kaye Scholer LLP
`250 West 55th Street
`New York, New York 10019-9710
`Telephone: 212.836.8000
`Fax: 212.836.8689
`Daniel.Reisner@arnoldporter.com
`Matthew.Wilk@arnoldporter.com
`
`Dated: February 28, 2022
`
`
`
`
`
`Alice S. Ho (Lim. Rec. No. L1162)
`Victoria Reines
`Jeremy Cobb
`Arnold & Porter Kaye Scholer LLP
`601 Massachusetts Ave., N.W.
`Washington D.C. 20001
`Tel: 202.942.5000
`Fax: 202.942.5999
`Alice.Ho@arnoldporter.com
`Victoria.Reines@arnoldporter.com
`Jeremy.Cobb@arnoldporter.com
`
`
`Respectfully Submitted,
`
`RAKOCZY MOLINO MAZZOCHI SIWIK LLP
`
`/Paul J. Molino/
`
`
`
`